

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Trial Protocol

Effect of Tai Chi vs Aerobic Exercise on Blood Pressure in Patients with Prehypertension: A Randomized Clinical Trial

17 1. Background

18 Prehypertension, defined as blood pressure (BP) in the range of 120-139/80-89 mmHg, was introduced
19 by the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of
20 High Blood Pressure in 2003 [1]. Prehypertension is highly prevalent and affects 25-50% of adults worldwide.
21 Compared with optimal BP, the prehypertension increases the risk of incident hypertension, cardiovascular
22 (CV) events and death [2], as it is related to risk factors such as high body mass index, metabolic syndrome,
23 dyslipidemia and impaired glucose metabolism [3,4]. Prehypertension increases the risk of incident
24 hypertension, with annual rates ranging from 8% to 20% in studies lasting 2-4 years, and 4% to 9% in longer-
25 term studies [5,6]. The Guidelines recommend that prehypertension population at low-moderate CV risk
26 should be offered lifestyle advice [7]. Moderate intensity of regular physical activity, as one of the lifestyles,
27 can reduce BP, as well as lower the risk of heart attack and stroke [8].

28 Aerobic exercise, is recommended as one of the lifestyles that can lower BP [9] and suggested in the
29 guidelines to help both the prevention and treatment of hypertension [7]. However, aerobic exercise has some
30 limitations. The exercise adherence is low and pace and venue also restrict effective training of aerobic
31 exercise. Other useful substitute exercise modes need to be proved effective in reducing BP. As a safe, low-
32 impact, enjoyable, and inexpensive form of exercise, that requires minimal equipment and space, Tai Chi is
33 beneficial to improve exercise adherence and is expected as a viable alternative to aerobic exercise [10,11].
34 Tai Chi guides people to concentrate on slow and fluid movements, covering all-round adjustments such as
35 balance, core strength, flexibility and so on [12]. Studies have shown that Tai Chi has a positive effect on
36 patients with cardiovascular diseases (CVD) [13], and it can have a beneficial impact on BP when combined
37 with other lifestyle forms changes [14]. Some studies have shown that after 12 weeks, 9 months or 12 months

38 of intervention, systolic blood pressure (SBP) in the Tai Chi group decreased significantly, suggesting that Tai
39 Chi exercise training can effectively reduce BP in patients with hypertension [15-18].

40 Therefore, the study aimed to assess the effect of Tai Chi intervention program, compared with aerobic
41 exercise, on the office BP, ambulatory blood pressure monitoring (ABPM) and home blood pressure
42 monitoring (HBPM) in patients with prehypertension. Based on previous studies, Tai Chi was hypothesized to
43 have better effects on lowering BP than aerobic exercise.

44

45 **2. Study design**

46 This protocol followed the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)
47 reporting guideline (Figure 1). The study setting is two hospitals in Beijing, China: Guang'anmen Hospital of
48 China Academy of Chinese Medical Sciences and Dongzhimen Hospital of Beijing University of Chinese
49 Medicine. The study has received approval from the Ethics Committee of two hospitals.

50 This study is a 12-month, parallel, randomized controlled trial, conducted in two centers. Patients with
51 prehypertension are randomized to one of two intervention groups: 12-month supervised Tai Chi held four
52 times a week, or 12-month supervised aerobic exercise. All groups will be followed up for 12 months.

53 A one-week induction period is designed for those who meet the inclusion criteria for prehypertension
54 screening; during this period, participants will receive Tai Chi education and train to exclude individuals who
55 cannot tolerate the exercises and improve study compliance. Outcome measurements are collected at baseline,
56 6 months, and 12 months (Table 1). The staff conducting the BP assessments and the statistician are blinded to
57 treatment tasks and groupings. The study flow chart shows an overview of the study procedure (Figure 2).

58

59 **Table 1.** Sequence of Primary and secondary outcomes measurement during intervention and follow-
 60 up

	Baseline	Month 6	Month 12
Time (days)	-7~0	180±14	360±14
Primary outcome variable			
SBP in office blood pressure ^a	×	×	×
Secondary outcome variables			
DBP in office blood pressure	×	×	×
ABPM ^b	×		×
Caloric assessment of diet ^c	×	×	×
HBPM	×	×	×
IPAQ ^d	×	×	×
SF-36	×		×
Blood taken	×		×
Urine taken	×		×
SCORE system	×		×

61 ^aSystolic blood pressure (SBP) in office blood pressure is the primary outcome at 12 months; the other
 62 collection times are secondary outcome variables. ^bAmbulatory blood pressure monitoring (ABPM) can

63 provide the average blood pressure estimates during the whole monitoring period, and provide average BP
64 during nighttime and daytime respectively, estimate the variability of BP. ^cAssess the average daily calorie
65 intake of participant for the nearly week. ^dUsed to assess the one-week total physical activity including
66 physical activity of occupation, transportation, housework and recreation.

67 Abbreviations: DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; IPAQ,
68 International Physical Activity Questionnaire; SF-36, Medical Outcome Survey Short-Form 36; SCORE,
69 Systematic COronary Risk Evaluation.

70


71 **Figure 1. SPIRIT figure.** Schedule Of enrolment, interventions, and assessments.

TIMEPOINT	STUDY PERIOD					
	Enrolment	Allocation	Intervention			Close-out
	Week -1	0	Month 1-5	Month 6	month 7-11	month 12
ENROLMENT:						
Eligibility screen	X					
Informed consent	X					
Allocation		X				
INTERVENTIONS:						
Tai Chi group			←————→			
Aerobic exercise group			←————→			
ASSESSMENTS:						
Baseline characteristics	X					
SBP in office blood pressure	X			X		X
DBP in office blood pressure	X			X		X
ABPM	X					X
Caloric assessment of diet	X			X		X
HBPM	X			X		X
IPAQ	X			X		X
SF-36	X					X
Blood taken	X					X
Urine taken	X					X
SCORE system	X					X
Adverse events				X		X

72

73 **Figure 2. Study flow chart.** SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood

74 pressure; ABPM, ambulatory blood pressure monitoring; HBPM, home blood pressure monitoring.



75

76

77 3. Eligibility Criteria

78 Patients who meet the classification of prehypertension [with a SBP in the range of 120 mmHg to 139
 79 mmHg and/or a diastolic blood pressure (DBP) in the range of 80 mmHg to 89 mmHg] are eligible to
 80 participate in this study [1]. Recruitment strategies include the distribution of flyers within the hospital as well
 81 as advertisements in print and online media, to ensure adequate enrollment of different study population.
 82 Potential participants will be contacted by phone and WeChat to assess whether they meet the basic eligibility
 83 criteria for the study. Those who meet the eligibility criteria are invited to come to the hospital for screening,
 84 in which case their eligibility criteria are verified. After a complete explanation of the study procedures, each
 85 eligible subject who agrees to participate provides informed consent, which is completed by the principal
 86 investigator or study coordinator. The study coordinator will inform participants of the schedule of the training
 87 sessions, including the date and time.

88 Participants are considered eligible for this study if they:

89 (1) are aged from 18 to 65 years;

90 (2) fulfill the classification of prehypertension: with a SBP in the range of 120 mmHg to 139 mmHg and/or
91 a DBP in the range of 80 mmHg to 89 mmHg [1];

92 (3) have no western medicine or traditional Chinese medicine, acupuncture and moxibustion were used to
93 control blood pressure (or the treatment was discontinued for 2 weeks);

94 (4) are willing to be randomized to Tai Chi group or aerobic exercise group;

95 (5) have ability to complete written questionnaires and operate electronic equipment independently;

96 (6) are able to give informed consent.

97 Exclusion criteria are: (1) diagnosed with diabetes mellitus and coronary heart disease;

98 (2) pregnant and lactating women;

99 (3) non-dominant arm circumference > 50 cm;

100 (4) body mass index (BMI) larger than 40.0 kg/m²;

101 (5) take benzodiazepines, antipsychotics or oral glucocorticoids (allowed to taken fluoxetine, paroxetine,
102 sertraline, fluvoxamine, citalopram and escitalopram stably within 3 months);

103 (6) with chronic kidney disease, with eGFR < 60 mL/min;

104 (7) diagnosed with Shy-Drager syndrome;

105 (8) alcoholism (male's alcohol intake is more than 25 g/day or 140 g/week or female's alcohol intake is
106 more than 15 g/day or 80 g/week);

107 (9) has played Tai Chi more than once a month in the past six months;

108 (10) plays vigorous sports activities more than three times a week;

109 (11) with musculoskeletal disorder or other disabling diseases lead to the inability to practice Tai Chi or do

110 aerobic exercise;

111 (12) current in clinical trials of other drugs or external therapies.

112

113 **4. Randomization and blinding**

114 Participants, after the induction period, who met all the eligibility criteria and provided written informed
115 consent will be randomly assigned to either Tai Chi or aerobic exercise (control) group, in a 1:1 ratio, with a
116 predicted sample size of 342 patients, 171 in each group. At the same time, the participants are stratified
117 according to SBP of 120–129 mmHg and DBP <80 mmHg, and SBP of 130–139 mmHg or DBP of 80–89
118 mmHg. At each stratum, the proportion of participants in the Tai Chi and aerobic exercise groups is also
119 randomly assigned in a 1:1 ratio. In order to ensure the concealment of allocation, a 24-hour central web-
120 based automated randomization system is adopted for all randomization processes, using the static random
121 method and the SAS9.4 software PROC PLAN process programming.

122 When allocation is complete, the outcome assessors who evaluate the effects of the treatments will receive
123 only the participant number, and then interpretation the data under blinded to group allocation. Only outcome
124 assessors are blinded so unblinding will not occur.

125

126 **5. Study intervention**

127 The maximum waiting time between baseline assessment and interventional therapy is 3 weeks. In order to
128 avoid the influence of seasonal factors on the disease, both Tai Chi and aerobic exercise groups are
129 simultaneously performed. Participants randomly assigned to Tai Chi or aerobic exercise will practice at
130 indoor activity room in or near Guang'anmen Hospital or Dongzhimen Hospital. The number of participants in
131 each class is limited to 20 to ensure the quality of teaching and learning.

132

133 ● *Lifestyle intervention*

134 Common interventions are health education and lifestyle guidance. Participants in both groups receive
135 dietary recommendations for weight control and salt intake. DASH eating plan is the best diet that can
136 effectively reduce BP [20]. During the study intervention, participants are advised to follow the DASH diet,
137 which is rich in fruits, vegetables and low-fat dairy foods and with reduced saturated and total fat.

138 ● *Tai Chi intervention*

139 The 24-form Yang-style Tai Chi consists of 24 standard movements. The four Tai Chi instructors each
140 have extensive experience and will explain and demonstrate Tai Chi principles, practice techniques and safety
141 precautions for each movement at the beginning of the study. The instructor will review these principles and
142 techniques, as throughout the study process and always practice with the participants, to timely and effectively
143 identify and correct the incorrect posture or movement. Participants will also be instructed to concentrate and
144 perform traditional Tai Chi breathing, while performing body movements. Moreover, all four instructors
145 completed the required human subject protection training before the beginning of intervention courses.

146 Each Tai Chi session will last for 60 min, including 10 min of warm-up exercise, 40 min of Tai Chi
147 teaching and/or practice, and 10 min of relaxation, and occur 4 times a week. Among them, there are no less
148 than twice centralized sessions per week, and for the rest practice, participants can practice at home and
149 upload videos. The instructor could modify and tailor-make for their Tai Chi exercises according to
150 participants' learning and athletic ability. In the initial eighth-week, the participants learn and practice step by
151 step. In each session, participants practice and learn 3 to 4 movements of Tai Chi. After all the 24 Tai Chi
152 forms had been learned (weeks 10 and 11), the Tai Chi instructor (experience > 10 years) will assess the
153 participants. After passing the assessment, the participants will participate in centralized sessions at least once

154 a week, and practice at home and upload videos for the other three times. Participants are required to sign in to
155 confirm the accurate attendance records, when they attend the Tai Chi session or practice at home. The
156 standard case report forms are used to record and verify the data collected for class attendance, to confirm
157 accurate attendance recordings. The study staff will monitor the participants by monthly home calls
158 throughout the 12-month intervention. Throughout the study, all sessions are regularly monitored and fed back
159 to ensure proper instruction.

160 ● *Aerobic exercise intervention*

161 Participants randomized to aerobic exercise will receive a supervised, group-format aerobic exercise
162 program. The aerobic exercises training protocol for prehypertension treatment consists of four 60-minute
163 sessions of moderate intensity exercises per week. The aerobic exercises include climbing stairs, jogging,
164 brisk walking and cycling. Each session includes several parts: 10 minutes of warm-up including low-intensity
165 exercise and dynamic stretching; 40 minutes of organized aerobic training, gradually developing from low
166 intensity to medium intensity; 10 minutes cool-down. The training in the sessions is progressive, and all
167 participants gradually increase the duration and intensity of the exercise. In all sessions, instructors will
168 closely monitor to ensure the comfort and safety of participants and to minimize adverse events. Heart rate
169 will be recorded during each session to monitor the intensity of exercise. During the 1-4 weeks, participants
170 are advised to achieve an individualized heart rate of 55% - 65% of estimated maximum heart rate according
171 to their age, and should reach 60% - 70% after 4 weeks. The maximum heart rate is estimated as " $208 - 0.7 \times$
172 age "[21]. Participants in aerobic exercise group will perform the above exercises 4 times a week, including
173 collective exercises no less than 1 time a week, and the rest 3 times of uploaded videos. A wrist wearable
174 device (HUAWEI band) is used to monitor heart rate. It uses an optical sensor to accurately calculate heart
175 rate through fluctuations in blood flow in the wrist. The data are uploaded to an app, where information is

176 stored for long time. The data collected for session attendance are recorded using standard case report forms.
177 The study team will contact the participants by monthly phone to monitor their adherence until the 12-month
178 follow-up evaluation. During the study process, all sessions are regularly monitored by the instructors and fed
179 back to ensure correct instruction for the group.

180

181 **6. Measurements**

182 Referring to the BP measurement method in the Guideline [22], the specific measurement method of the
183 study is as follows. A quiet room is set up for measurement of BP. The upper arm medical electronic
184 sphygmomanometer certified by the internationally accepted protocol is used (Omron HBP-1300). The
185 patients are asked to rest, sitting in a chair, for >10 min, and the first BP measurement is conducted following
186 the rest period. The participant and the researcher should not talk during the rest period or the measurement.
187 The interval of repeated measurements is 1-2 minutes. When the difference between the first two
188 measurements is greater than 10 mmHg, additional measurements are taken. The average of the last two
189 readings is recorded to estimate the individual's level of BP.

190 Participants receive 24 h-ambulatory blood pressure monitoring (Welch Allyn ABPM 6100). The 24-hour
191 ABPM is programmed to automatically obtain BP records, with the instrument set to obtain readings every 30
192 minutes throughout the day and every 1 hour at night. ABPM can provide the average BP estimates during the
193 whole monitoring period, and provide average BP during nighttime and daytime respectively, estimate the
194 variability of BP.

195 Participants are given a free upper-arm cuff device (Lifesense i5S), which enables automatically stores
196 multiple readings, and educated on its use. Referring to the home BP monitoring measurement in the
197 Guideline [7], measurements are taken in a quiet room after 5 min of rest, with the participant seated.

198 Participants are instructed to obtain home BP measurements two times in the morning after voiding and before
199 eating or vigorous exercise and two times in the evening, with 1 minute apart between readings. Mean home
200 BP is reliable, using the average of two morning and two evening BP readings for at least three consecutive
201 days in one week minimum in each month [23], at the same time, can being used to estimate the variability of
202 BP.

203

204 **7. Data collection and management**

205 ● *Plans for assessment and collection of outcomes*

206 The researchers shall fill in data to case report forms (CRF) accurately, completely, and timely based on
207 original observations of the subjects. The auditor should monitor whether all CRFs are consistent with the
208 source data and raise questions at any time when any problem occurs. If there are errors and omissions, the
209 researchers should correct them in time.

210 ● *Data management*

211 All data will initially be entered legibly in the paper CRF. If an error made, it will be crossed through with a
212 single line to ensure that the original entry can still be read. The correct entry will then be inserted clearly. The
213 amendment will be initialed and dated by the person making the correction immediately. It is not permitted to
214 overwrite or use correction fluid. Ensure that paper-based CRF data are securely input into Electronic Data
215 Capture (EDC) system. Access will be restricted to site personnel, trial monitors and data management team.
216 EDC system provides range checks for data values to ensure and improve data quality. Researchers are
217 responsible for ensuring the accuracy of all data entered and recorded in the paper CRF and EDC system.

218

219 **8. Relevant concomitant care permitted or prohibited during the trial**

220 During the run-in period and the intervention period, antihypertensive drugs or antihypertensive treatment
221 will not be allowed to be used. If the participant has increased BP and cannot tolerate the increased BP, which
222 should be treated immediately, it is not advisable to continue the trial, and the researcher should consider
223 terminating the intervention and switching to another type of clinical treatment.

224

225 **9. Provisions for post-trial care**

226 Participants will be assessed on a case-by-case basis across all participating sites and will be given the
227 option to remain on the centralized exercise training after completion of the trial if there appears to be a
228 benefit to them. If serious adverse events occur during the study period, the participants are also required to be
229 followed up after the study period. Appropriate measures will be taken to fully protect the interests of
230 participants, such as outpatient or inpatient care or referrals to other specialists.

231

232 **10. Outcomes and Follow-up**

233 At enrollment, the essential information of participants' sex, age, nation, income, education level,
234 professional characteristics, personal history, family history, height, weight, waist circumference, hip
235 circumference, eating habits and caloric intake are collected. Overall assessment of BP is focused on.
236 Outcomes are assessed at baseline, 6 months, and 12 months (at the end of the intervention).

237 ● *Primary outcome*

238 The primary outcome is the comparison of SBP of office blood pressure change from baseline to 12 months
239 between Tai Chi group and aerobic exercise group.

240 ● *Secondary outcomes*

241 BP monitoring methods of office blood pressure, ABPM and HBPM are used at the same time to detect BP

242 in multiple dimensions. The secondary endpoints are as following:

243 (1) the comparison of DBP of office blood pressure change from baseline to 12 months between Tai Chi
244 group and aerobic exercise group; (2) the comparison of BP and the variability of BP assessed through ABPM
245 change from baseline to 12 months between Tai Chi group and aerobic exercise group; (3) the comparison of
246 BP assessed through HBPM change from baseline to 12 months between Tai Chi group and aerobic exercise
247 group.

248

249 **11. Monitoring of Adverse Events**

250 Adverse events must be registered during the study period, which refers to the medical conditions not
251 considered as end points of study. Study participants are monitored for the occurrence of adverse events,
252 during each encounter during the study intervention. A study telephone number is provided to the participants
253 to report adverse events throughout the study. All adverse events are recorded in the case report form during
254 the study intervention.

255

256 **12. Criteria for study withdrawal**

257 Individuals who decide to no longer participate in the study or who are lost to follow-up (failure to attend
258 the prescheduled visits or cannot be reached by telephone call) can be withdrawn from the study.

259

260 **13. Confidentiality**

261 Participant individual identification numbers are used to track data collection documents. All data will be
262 kept strictly confidential and only accessed by members of the trial team. Paper CRFs are stored in a locked
263 file cabinet. Access to EDC system is password protected and restricted to the trial team. This protocol, CRFs,

264 and other documents and materials related to the trial will be kept strictly confidential and will not be
265 disclosed to third parties unless expressly agreed upon by the principal investigator in advance. Staff of the
266 investigators involved in this trial are also bound by the agreement.

267

268 **14. Statistical Analysis**

269 The data of all participants will be analyzed according to the group to which they were originally assigned,
270 regardless of whether having adhered to the treatment and study procedures. Descriptive statistics, such as the
271 mean (SD) or percentage, are used to summarize baseline characteristics and unadjusted study outcome
272 measures, while assessing intergroup equivalence at baseline. At the end of the study, treatment analysis will
273 be performed according to the protocol. Analysis of variance of continuous variables and χ^2 (or Fisher exact)
274 test for categorical variables are used to compare baseline demographic descriptions and primary and
275 secondary outcome measures of each group. For continuous variables, the differences between the average
276 variations from baseline values and their respective 95% CIs will be calculated. If any characteristic is
277 substantially different at baseline, it will be adjusted in a mixed-model regression analysis. To avoid multiple
278 comparisons, differences between groups will be assessed only if the overall effect of treatment is significant.
279 The source data will be registered in the paper CRF and EDC system, and the pattern of missing data will be
280 evaluated before data analyzing. Missing data will be processed through multiple imputation using a set of
281 baseline characteristics, and 6-month and 12-month results. All analyses will be conducted using IBM SPSS
282 (IBM Corp) or Stata (release 13; StataCorp LP). Level of statistical significance will be set at 0.05.

283 ● *Sample Size*

284 The sample size calculation was based on the comparison of the office SBP drop of individuals in the Tai
285 Chi group and the aerobic exercise group. According to the average reduction of SBP in the studies conducted

286 before the start of the trial [15,19], using a conservative estimate, we hypothesized that the SBP in the Tai Chi
287 group would be reduced by 4.6 mmHg more than the aerobic exercise group. Further conservatively assuming
288 an SD of 13.4 of both groups. We estimate a loss of follow-up of 20% and 80% power at a two-sided α level
289 of 0.05. Therefore, 171 participants per group and 342 participants in total is the reasonable sample size of this
290 study. The analyses were performed using PASS version 15.0.

291 ● *Study Outcomes*

292 The primary outcome measure was the change in office SBP from baseline to 12 months. Secondary
293 outcomes included mean changes in office SBP at 6 months; mean changes in office DBP at 6 and 12 months;
294 mean changes in 24-h Ambulatory BP (24-h ambulatory SBP, 24-h ambulatory DBP, daytime ambulatory
295 SBP, daytime ambulatory DBP, nighttime ambulatory SBP and nighttime ambulatory DBP), BP assessed
296 through HBPM at 12 months; and adverse events (e.g., being hospitalized, or death by any cause), including
297 adverse effects during or after the exercise sessions (e.g., severe hypotension). Other assessments included
298 adherence (assessed via Tai Chi or aerobic exercise sessions) and safety evaluations.

299 ● *Data Set*

300 **Intention-to-treat (ITT)** refers to all eligible patients who were randomized to treatment, include drop-out
301 cases. Multiple imputation method will be preferred for analyzing the missing data.

302 **Safety set (SS)** refers to the actual data for subjects who receive at least one intervention after
303 randomization and for whom safety indicators are documented. The incidence of adverse reactions is
304 calculated using the number of cases in the safety set.

305 **Adverse events:** Will be analyzed, with the number of cases, category, and severity of occurrences counted
306 separately and their relationship to the intervention.

307

308 **15. Oversight and monitoring**

309 The study group provided coordination and day to day support for the trial. The study leader, Yanwei Xing,
310 supervised the design of the study and will supervise and guide the implementation of the trial. Study leader
311 was responsible for all aspects of local organization, including identifying potential recruits and taking
312 consensus. The trial steering committee is composed of the study leader (Xing), on-site principal investigators
313 of each hospital, and coinvestigators. Questions that arise during the research process will be submitted to the
314 committee for decision-making. Finally, clinical research associates (CRAs) will supervise the study progress
315 at any time and hold a meeting every three months.

316 The Data Monitoring Committee (DMC) is consisting by a doctor whose major is clinical cardiovascular
317 disease, a scientific researcher whose major is clinical trial methodology and a statistician. DMC is
318 responsible for safety monitoring, reviewing, and evaluating the detailed information of adverse events
319 between groups. According to the evaluation results, DMC could give suggestions to terminate the trial in
320 advance, or take measures to reduce the risk of adverse events and adjust the study protocol. In the middle of
321 the trial, the research team will conduct interim analysis. If the analysis result is consistent with the hypothesis,
322 the test will be continued. If it is inconsistent or even contrary, the expert committee will be consulted to
323 decide whether to continue the test, expand the sample size, or terminate the test.

324

325 **16. Plans for auditing trial conduct**

326 The monitoring will be conducted by the principal investigator, on-site principal investigators, and DMC
327 every three months, as an audit of trial conduct. Annual progress reports and interim report are provided to the
328 funding agent.

329

330 **17. Plans for communicating important protocol amendments**

331 Any changes to the protocol will notify the funding agent first then will notify the centers and that a copy of
332 the revised protocol will be added to the Investigator Site File. All subsequent substantial protocol
333 amendments will be documented and submitted to the Ethics Committee for approval before implementation.
334 The principal investigator at each site is responsible for ensuring that all subsequent amendments gain the
335 necessary approval.

336

337 **18. References**

- 338 1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention,
339 Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (Dallas, Tex. : 1979)
340 2003;42(6):1206-52.
- 341 2. Egan BM, Stevens-Fabry S. Prehypertension--prevalence, health risks, and management strategies. Nat Rev
342 Cardiol. 2015;12(5):289-300. Epub 2015 Feb 17.
- 343 3. Ganguly SS, Al-Shafae MA, Bhargava K, Duttagupta KK. Prevalence of prehypertension and associated
344 cardiovascular risk profiles among prediabetic Omani adults. BMC public health 2008;8:108.
- 345 4. Grotto I, Grossman E, Huerta M, Sharabi Y. Prevalence of prehypertension and associated cardiovascular
346 risk profiles among young Israeli adults. Hypertension (Dallas, Tex. : 1979) 2006;48(2):254-9.
- 347 5. Egan BM, Stevens-Fabry S. Prehypertension--prevalence, health risks, and management strategies. Nature
348 reviews. Cardiology 2015;12(5):289-300.
- 349 6. Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis.
350 BMC medicine 2013;11:177.
- 351 7. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial

- 352 hypertension. *European heart journal* 2018;39(33):3021-104.
- 353 8. Grundy SM, Stone NJ, Bailey AL, et al. 2018
354 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the
355 Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart
356 Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;139(25):e1082-e143.
- 357 9. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults
358 from the American College of Sports Medicine and the American Heart Association. *Circulation*
359 2007;116(9):1081-93.
- 360 10. Wayne PM, Kaptchuk TJ. Challenges inherent to t'ai chi research: part I--t'ai chi as a complex
361 multicomponent intervention. *J Altern Complement Med.* 2008 Jan-Feb;14(1):95-102.
- 362 11. Wayne PM, Kaptchuk TJ. Challenges inherent to t'ai chi research: part II-defining the intervention and
363 optimal study design. *J Altern Complement Med.* 2008 Mar;14(2):191-7.
- 364 12. Zheng S, Kim C, Lal S, Meier P, Sibbritt D, Zaslowski C. The Effects of Twelve Weeks of Tai Chi
365 Practice on Anxiety in Stressed But Healthy People Compared to Exercise and Wait-List Groups-A
366 Randomized Controlled Trial. *Journal of clinical psychology* 2018;74(1):83-92.
- 367 13. Pan L, Yan J, Guo Y, Yan J. Effects of Tai Chi training on exercise capacity and quality of life in patients
368 with chronic heart failure: a meta-analysis. *European journal of heart failure* 2013;15(3):316-23.
- 369 14. Maris SA, Quintanilla D, Taetzsch A, et al. The combined effects of tai chi, resistance training, and diet on
370 physical function and body composition in obese older women. *Journal of aging research*
371 2014;2014:657851.
- 372 15. Chan AWK, Chair SY, Lee DTF, et al. Tai Chi exercise is more effective than brisk walking in reducing
373 cardiovascular disease risk factors among adults with hypertension: A randomised controlled trial.

- 374 International journal of nursing studies 2018;88:44-52.
- 375 16. Ma C, Zhou W, Tang Q, Huang S. The impact of group-based Tai chi on health-status outcomes among
376 community-dwelling older adults with hypertension. *Heart & lung: the journal of critical care*
377 2018;47(4):337-44.
- 378 17. Sun J, Buys N. Community-Based Mind-Body Meditative Tai Chi Program and Its Effects on
379 Improvement of Blood Pressure, Weight, Renal Function, Serum Lipoprotein, and Quality of Life in
380 Chinese Adults With Hypertension. *The American journal of cardiology* 2015;116(7):1076-81.
- 381 18. Tsai JC, Wang WH, Chan P, et al. The beneficial effects of Tai Chi Chuan on blood pressure and lipid
382 profile and anxiety status in a randomized controlled trial. *Journal of alternative and complementary*
383 *medicine (New York, N.Y.)* 2003;9(5):747-54.
- 384 19. Wu Y, Johnson BT, Chen S, et al. Tai Ji Quan as antihypertensive lifestyle therapy: A systematic review
385 and meta-analysis. *J Sport Health Sci.* 2020: S2095-2546(20)30038-7.
- 386 20. Schwingshackl L, Chaimani A, Schwedhelm C, et al. Comparative effects of different dietary approaches
387 on blood pressure in hypertensive and pre-hypertensive patients: A systematic review and network
388 meta-analysis. *Critical reviews in food science and nutrition* 2019;59(16):2674-87.
- 389 21. Tanaka H, Monahan KD, Seals DR. Age-predicted maximal heart rate revisited. *Journal of the American*
390 *College of Cardiology* 2001;37(1):153-6.
- 391 22. Whelton PK, Carey RM, Aronow WS, et al. 2017
392 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,
393 Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American
394 College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
395 *Hypertension (Dallas, Tex. : 1979)* 2018;71(6):e13-e115.

396 23. Bello NA, Schwartz JE, Kronish IM, et al. Number of Measurements Needed to Obtain a Reliable
397 Estimate of Home Blood Pressure: Results From the Improving the Detection of Hypertension Study.
398 Journal of the American Heart Association 2018;7(20):e008658.

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

Statistical Analysis

420

421

Effect of Tai Chi vs Aerobic Exercise on Blood Pressure in Patients with

422

Prehypertension: A Randomized Clinical Trial

423

424

425

426

427

428

429

430

431

432

433

434 **1. Study Objective**

435 To assess the efficacy of Tai Chi versus aerobic exercise in patients with prehypertension.

436

437 **2. Study Design**

438 **2.1 Sample Size**

439 The sample size calculation was based on the comparison of the office SBP drop of individuals in the Tai
440 Chi group and the aerobic exercise group. According to the average reduction of SBP in the studies conducted
441 before the start of the trial [1-2], using a conservative estimate, we hypothesized that the SBP in the Tai Chi
442 group would be reduced by 4.6 mmHg more than the aerobic exercise group. Further conservatively assuming
443 an SD of 13.4 of both groups. We estimate a loss of follow-up of 20% and 80% power at a two-sided α level
444 of 0.05. Therefore, 171 participants per group and 342 participants in total is the reasonable sample size of this
445 study. The analyses were performed using PASS version 15.0.

446

447 **2.2 Randomization and Blinding**

448 Participants, after the induction period, who met all the eligibility criteria and provided written informed
449 consent will be randomly assigned to either Tai Chi or aerobic exercise (control) group, in a 1:1 ratio, with a
450 predicted sample size of 342 patients, 171 in each group. At the same time, the participants are stratified
451 according to SBP of 120–129 mmHg and DBP <80 mmHg, and SBP of 130–139 mmHg or DBP of 80–89
452 mmHg. At each stratum, the proportion of participants in the Tai Chi and aerobic exercise groups is also
453 randomly assigned in a 1:1 ratio. In order to ensure the concealment of allocation, a 24-hour central web-
454 based automated randomisation system is adopted for all randomisation processes, using the static random
455 method and the SAS9.4 software PROC PLAN process programming.

456 When allocation is complete, the outcome assessors who evaluate the effects of the treatments will receive

457 only the participant number, and then interpretation the data under blinded to group allocation. Only outcome
458 assessors are blinded so unblinding will not occur.

459

460 **3. Study Outcomes**

461 The primary outcome measure was the change in office SBP from baseline to 12 months. Secondary
462 outcomes included mean changes in office SBP at 6 months; mean changes in office DBP at 6 and 12 months;
463 mean changes in 24-h Ambulatory BP (24-h ambulatory SBP, 24-h ambulatory DBP, daytime ambulatory
464 SBP, daytime ambulatory DBP, nighttime ambulatory SBP and nighttime ambulatory DBP), BP assessed
465 through HBPM at 12 months; and adverse events (e.g., being hospitalized, or death by any cause), including
466 adverse effects during or after the exercise sessions (e.g., severe hypotension). Other assessments included
467 adherence (assessed via Tai Chi or aerobic exercise sessions) and safety evaluations.

468

469 **4. Data Set**

470 **Intention-to-treat (ITT)** refers to all eligible patients who were randomized to treatment, include drop-out
471 cases. Multiple imputation method will be preferred for analyzing the missing data.

472 **Safety set (SS)** refers to the actual data for subjects who receive at least one intervention after
473 randomization and for whom safety indicators are documented. The incidence of adverse reactions is
474 calculated using the number of cases in the safety set.

475 **Adverse events:** Will be analyzed, with the number of cases, category, and severity of occurrences counted
476 separately and their relationship to the intervention.

477 **5. Statistical Analysis**

478 **5.1 General considerations**

479 The data of all participants will be analyzed according to the group to which they were originally assigned,
480 regardless of whether having adhered to the treatment and study procedures. Descriptive statistics, such as the
481 mean (SD) or percentage, are used to summarize baseline characteristics and unadjusted study outcome
482 measures, while assessing intergroup equivalence at baseline. At the end of the study, treatment analysis will
483 be performed according to the protocol. Analysis of variance of continuous variables and χ^2 (or Fisher exact)
484 test for categorical variables are used to compare baseline demographic descriptions and primary and
485 secondary outcome measures of each group. For continuous variables, the differences between the average
486 variations from baseline values and their respective 95% CIs will be calculated. If any characteristic is
487 substantially different at baseline, it will be adjusted in a mixed-model regression analysis. To avoid multiple
488 comparisons, differences between groups will be assessed only if the overall effect of treatment is significant.
489 The source data will be registered in the paper CRF and EDC system, and the pattern of missing data will be
490 evaluated before data analyzing. All analyses will be conducted using IBM SPSS (IBM Corp) or Stata (release
491 13; StataCorp LP). Level of statistical significance will be set at 0.05.

492

493 **5.2 Analysis of the primary outcome**

494 The primary outcome is the change (difference) in office SBP from baseline to the end of the 12-
495 month intervention. Mean differences will be expressed with their two-sided 95% confidence interval.
496 Between-group differences in the change from baseline to the end of the 12-month intervention will
497 be tested with Student's independent t-test or the Mann-Whitney U test. Student's paired t-tests or
498 the Wilcoxon signed-rank test will be performed for within-group comparisons from baseline to the
499 end of the 12-month intervention.

500

501 **5.3 Analysis of the secondary outcomes**

502 Secondary outcomes included mean changes in office SBP at 6 months; mean changes in office
503 DBP at 6 and 12 months; mean changes in 24-h Ambulatory BP (24-h ambulatory SBP, 24-h
504 ambulatory DBP, daytime ambulatory SBP, daytime ambulatory DBP, nighttime ambulatory SBP
505 and nighttime ambulatory DBP), BP assessed through HBPM at 12 months; and adverse events (e.g.,
506 being hospitalized, or death by any cause), including adverse effects during or after the exercise
507 sessions (e.g., severe hypotension). The mean change in the secondary outcomes will be analyzed
508 using the same statistical methods as those used for the primary outcome. Between-group differences
509 in the change from baseline to 6 and 12 months will be tested with Student's independent t-test or the
510 Mann-Whitney U test. Student's paired t-tests or the Wilcoxon signed-rank test will be performed for
511 within-group comparisons from baseline to 6 and 12 months.

512

513 **6. References**

- 514 1. Chan AWK, Chair SY, Lee DTF, et al. Tai Chi exercise is more effective than brisk walking in reducing
515 cardiovascular disease risk factors among adults with hypertension: A randomised controlled trial.
516 International journal of nursing studies 2018;88:44-52.
- 517 2. Wu Y, Johnson BT, Chen S, et al. Tai Ji Quan as antihypertensive lifestyle therapy: A systematic review
518 and meta-analysis. J Sport Health Sci. 2020: S2095-2546(20)30038-7.

519